Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Incyte Corporation — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.61, while Incyte Corporation trades at $121.06 (market cap $24.54B). Which is the better fit depends on your goals.
| GSG | INCY | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $129.93 |
52-Week Low | $22.06 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $32.62, up 0.93% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The ETF's performance is heavily tied to energy commodities, which drove strong gains in H1 2026, though recent analyst sentiment has turned cautious due to sector volatility. Key support is at $31, with resistance at $32.
The outlook for GSG hinges on commodity market dynamics, particularly energy prices, offering exposure to broad commodities but facing risks from geopolitical tensions and volatility. Investor caution is warranted as analysts highlight increased risks near current price levels, with a recent downgrade to Hold reflecting concerns over sustained outperformance.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
